Managers / Q1 2021 · view latest →
SV Health Investors, LLC
CIK 0001587143 · ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON, MA, 02108 · 617-367-8100
Summary
Sv Health Investors, LLC reported $267M in U.S.-listed holdings across 8 positions for Q1 2021.
The portfolio is heavily concentrated: AHCO alone accounts for 40.1% of reported value.
Compared with Q4 2020, the fund opened 2 new positions and exited 3.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 61.7% · $165M
- ADR · 21.4% · $57M
- Other · 16.9% · $45M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2020 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| AHCOADAPTHEALTH CORP. | NEW | +2.91M | 2.91M | +$107M | $107M |
| ASENSUS SURGICAL, INC. | NEW | +510.1K | 510.1K | +$2M | $2M |
| AMERICAN WELL CORP | SOLD OUT | −1.66M | 0 | −$42M | $0 |
| KALVISTA PHARMACEUTICALS INC | SOLD OUT | −1.72M | 0 | −$26M | $0 |
| TRANSENTERIX INC | SOLD OUT | −510.1K | 0 | −$319,000 | $0 |
| AVROBIO INC | TRIMMED | −916.6K | 275.0K | −$13M | $3M |
| BCYCBICYCLE THERAPEUTICS PLC | HELD | +0 | 1.92M | +$23M | $57M |
| MISONIX, INC. | HELD | +0 | 1.69M | +$12M | $33M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2021
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | AHCOADAPTHEALTH CORP.history → | COM | 40.09% | $107M | 2.91M |
| 2 | BCYCBICYCLE THERAPEUTICS PLChistory → | SPONSORED ADS | 21.43% | $57M | 1.92M |
| 3 | SUTRO BIOPHARMA INC | COM | 15.56% | $42M | 1.82M |
| 4 | MISONIX, INC. | COM | 12.43% | $33M | 1.69M |
| 5 | DECIPHERA PHARMACEUTICALS INC | COM | 7.56% | $20M | 450.0K |
| 6 | AVROBIO INC | COM | 1.31% | $3M | 275.0K |
| 7 | X4 PHARMACEUTICALS INC | COM | 1.00% | $3M | 311.5K |
| 8 | ASENSUS SURGICAL, INC. | COM NEW | 0.62% | $2M | 510.1K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2022 | $32M | 4 | Nov 7, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $44M | 5 | Aug 12, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $83M | 5 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $155M | 6 | Feb 11, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $204M | 8 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $230M | 7 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $267M | 8 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $208M | 9 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $197M | 10 | Nov 12, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $144M | 10 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $119M | 10 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $165M | 10 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $142M | 10 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $149M | 9 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $170M | 8 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $162M | 9 | Feb 14, 2019 | 13F-HR | changes · EDGAR ↗ |
Other Included Managers
This filing reports holdings on behalf of 2 additional managers.
- SVLSF VI, LLC028-19256
- SV Life Sciences Fund VI (GP), L.P.028-19255
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.